AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 292 min read$BHC

Bausch Health (BHC) Q3 2026 Earnings Call Transcript

Bausch Health (BHC) reported Q3 2026 earnings, marking 4 consecutive quarters of year-over-year revenue and adjusted EBITDA growth. The company exceeded $1 billion in quarterly adjusted EBITDA and reduced net debt by over $500 million. Salix revenue increased 16%, while international business grew mid-single-digit. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 4:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:53 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bausch Health (BHC) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BHCBullishHigh
01

Why it matters

The earnings beat and guidance raise are likely to drive buying interest, especially from dividend‑seeking investors.

02

Market read

First‑report earnings with material numbers and guidance lift make this a high‑impact news item for BHC.

03

What to watch

Potential headwinds from foreign exchange exposure and upcoming regulatory reviews are not addressed in the call.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

The transcript provides the first public disclosure of Bausch Health's Q3 2026 financials and updated outlook.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Bausch Health reported Q3 2026 results with revenue of $2.941B, adjusted EBITDA of $1.305B and raised full‑year guidance.

Expected impact

likely upward pressure as investors price in stronger earnings and higher guidance

Evidence & confidence

The company delivered double‑digit growth, exceeded $1B adjusted EBITDA and lifted guidance, a material new development.

Market effects

Sector

Strong performance may lift the broader health‑care and specialty pharma sector.

Regional

Positive for North American biotech/health‑care indices.

Global

Limited to investors tracking specialty pharma earnings.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock could face a short‑term pullback.

Key entities

  • Executive
    Thomas J. Appio

    Interim CEO of Bausch and Lomb, speaker on the call.

  • Executive
    Jean‑Jacques Charhon

    Presented detailed financial results.

Read at source← All news

StoryBausch Health posts Q3 earnings beat, raises FY2026 outlook and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 29
$BHCMedAI 8/10

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health (BHC) reported Q3 revenue growth in international and Solta Medical segments, with Solta seeing 18% reported growth. The company reduced net debt by $521M in Q3 and announced a $50M share repurchase program. BHC updated its 2026 outlook, expecting 8% revenue growth and 13% adjusted EBITDA growth. Management remains focused on portfolio performance and operational improvements.

finance.yahoo.com2 min
OCT 28
$BHCHighAI 8/10

[Bausch Health Companies Q3 2026 Earnings Call] Bausch Health Raises Guidance Again as Quarterly Adjusted EBITDA Tops $1 Billion for First Time; Warns of $400–$500 Million XIFAXAN Headwind in 2027

Bausch Health (BHC) reported Q3 2026 revenue of $2.94B, up 10% YoY, with adjusted EBITDA surpassing $1B for the first time. The company raised full-year guidance but warned of $400M-$500M XIFAXAN headwind in 2027 due to Medicare rebates. Salix segment grew 16%, driven by XIFAXAN. Net debt reduced by $1B YTD, with plans for debt redemptions and share repurchases.

finance.biggo.com3 min
OCT 28
$BHCHighAI 8/10

Bausch Health Q3FY26 Results: Adjusted EBITDA up 32% to $1.3 billion

Bausch Health reported a 32% YoY increase in adjusted EBITDA to $1.305 billion for Q3FY26, exceeding $1 billion for the first time. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and cash flow, citing strong performance. Net debt was reduced by $521 million during the quarter. Salix segment drove growth with a 16% revenue increase, while Solta Medical saw reported revenue grow 18% but organic revenue decline 4%.

scanx.trade3 min